-
Logo Downloads
-
Photo Downloads
Leadership Headshots
CRISPR/Cas9 ResourcesNTLA-2001 and Transthyretin (ATTR) Amyloidosis Fact SheetIntellia TherapeuticsCRISPR/Cas9 – How it Works (Video)Intellia TherapeuticsThe Nobel Prize in Chemistry 2020The Royal Swedish Academy of SciencesCAR T Cells: Engineering Patients’ Immune Cells to Treat Their CancersNational Institutes of Health, National Cancer InstituteChief Medical Officer annual report 2016: generation genomeUnited Kingdom Department of Health & Social CareThe promise of human genome editing for rare and genetic diseaseAcademy of Medical Science’s 2019 FORUM Annual LectureHuman Genome Editing: Science, Ethics, and GovernanceThe National Academies of Sciences, Engineering, MedicineThe Future of Therapeutic Genome Editing in European Healthcare SystemsAlliance for Regenerative Medicine“CRISPR Guide,”AddgeneWhat are genome editing and CRISPR-Cas9?National Institutes of Health, Genetic Home ReferenceJoint Statement of: Position Regarding Human Germline Gene Editing (Dec. 2015)Intellia Therapeutics & CRISPR Therapeutics
Stay in the Know
Media Contacts
Julie Ferguson
Interim Head of External Affairs & Communications
Follow Us on Social Media
@intelliatweets
From July 5 – July 9, Intellia will be closed for our annual summer shutdown. This is just one of the many great employee benefits that we offer! Check out our other benefits here: https://t.co/fpNp8aEgxC #IamIntellia #CRISPR #genomeediting https://t.co/EpNHKMe77j
@intelliatweets
From all of us at Intellia, we wish you a safe, healthy and fun #IndependenceDay! #FourthofJuly https://t.co/Ot87KA4ojC
@intelliatweets
As we wrap up an exciting week, we are thinking again of the thousands of people worldwide living with #ATTR amyloidosis. We intend to move rapidly to advance NTLA-2001 through the clinic in hopes of halting and even reversing the painful progression of all types of #ATTR. https://t.co/eoGSpFGg6F